Antonio Marchesoni

Summary

Affiliation: University of Milan
Country: Italy

Publications

  1. ncbi request reprint Step-down approach using either cyclosporin A or methotrexate as maintenance therapy in early rheumatoid arthritis
    Antonio Marchesoni
    G Pini Orthopaedic Institute, Milan, Italy
    Arthritis Rheum 47:59-66. 2002
  2. doi request reprint Psoriatic Disease: Update on Traditional Disease-modifying Antirheumatic Drugs
    Antonio Marchesoni
    From the UOC Day Hospital of Rheumatology, G Pini Orthopedic Institute, Milan Academic Rheumatology Unit, Department of Medicine and Health Sciences, University of Molise, Campobasso and the Rheumatology Unit, Department of Medical Sciences, University of Cagliari, Cagliari, Italy A Marchesoni, MD, UOC Day Hospital of Rheumatology, G Pini Orthopedic Institute E Lubrano, MD, PhD, Academic Rheumatology Unit, Department of Medicine and Health Sciences, University of Molise A Cauli, MD, PhD, Rheumatology Unit, Department of Medical Sciences, University of Cagliari M Ricci, MD, UOC Day Hospital of Rheumatology, G Pini Orthopedic Institute M Manara M, MD, UOC Day Hospital of Rheumatology, G Pini Orthopedic Institute
    J Rheumatol Suppl 93:61-4. 2015
  3. doi request reprint Entheseal power Doppler ultrasonography: a comparison of psoriatic arthritis and fibromyalgia
    Antonio Marchesoni
    UOC Day Hospital of Rheumatology and Division of Rheumatology, G Pini Orthopedic Institute, Milan, Italy
    J Rheumatol Suppl 89:29-31. 2012
  4. doi request reprint Classification and clinical assessment
    A Marchesoni
    UO Day Hospital di Reumatologia, Istituto Ortopedico G Pini, Milano
    Reumatismo 64:79-87. 2012
  5. doi request reprint Identification of the clinical features distinguishing psoriatic arthritis and fibromyalgia
    Antonio Marchesoni
    UOC Day Hospital of Rheumatology, Istituto Ortopedico Gaetano Pini, Piazza A Ferrari 1, 20122 Milan, Italy
    J Rheumatol 39:849-55. 2012
  6. doi request reprint Multidisciplinary focus on methotrexate in psoriatic disesase
    Antonio Marchesoni
    U O C Day Hospital of Rheumatology, G Pini Orthopaedic Institute, 20122 Milan, Italy
    J Rheumatol Suppl 83:56-8. 2009
  7. ncbi request reprint The Italian registry of aggressive rheumatoid arthritis -- the GIARA project
    Antonio Marchesoni
    UOC Rheumatology Day Hospital, G Pini Orthopaedic Institute, University of Milan, Milan, Italy
    J Rheumatol 34:2374-81. 2007
  8. doi request reprint TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice
    Antonio Marchesoni
    Day Hospital of Rheumatology, G Pini Orthopaedic Institute, Milan, Italy
    Ann N Y Acad Sci 1173:837-46. 2009
  9. doi request reprint An Italian shared dermatological and rheumatological proposal for the use of biological agents in psoriatic disease
    A Marchesoni
    UOC DH of Rheumatology, G Pini Orthopaedic Institute, Milan, Italy
    J Eur Acad Dermatol Venereol 24:578-86. 2010
  10. ncbi request reprint Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone
    A Marchesoni
    Rheumatology Department, University of Milan, Italy
    Rheumatology (Oxford) 42:1545-9. 2003

Collaborators

Detail Information

Publications35

  1. ncbi request reprint Step-down approach using either cyclosporin A or methotrexate as maintenance therapy in early rheumatoid arthritis
    Antonio Marchesoni
    G Pini Orthopaedic Institute, Milan, Italy
    Arthritis Rheum 47:59-66. 2002
    ....
  2. doi request reprint Psoriatic Disease: Update on Traditional Disease-modifying Antirheumatic Drugs
    Antonio Marchesoni
    From the UOC Day Hospital of Rheumatology, G Pini Orthopedic Institute, Milan Academic Rheumatology Unit, Department of Medicine and Health Sciences, University of Molise, Campobasso and the Rheumatology Unit, Department of Medical Sciences, University of Cagliari, Cagliari, Italy A Marchesoni, MD, UOC Day Hospital of Rheumatology, G Pini Orthopedic Institute E Lubrano, MD, PhD, Academic Rheumatology Unit, Department of Medicine and Health Sciences, University of Molise A Cauli, MD, PhD, Rheumatology Unit, Department of Medical Sciences, University of Cagliari M Ricci, MD, UOC Day Hospital of Rheumatology, G Pini Orthopedic Institute M Manara M, MD, UOC Day Hospital of Rheumatology, G Pini Orthopedic Institute
    J Rheumatol Suppl 93:61-4. 2015
    ..The studies published in the examined time frame confirm that MTX, SSZ, LEF, and CSA have moderate symptom-modifying effect on psoriatic synovitis, and probably little effect on the other manifestations of PsA. ..
  3. doi request reprint Entheseal power Doppler ultrasonography: a comparison of psoriatic arthritis and fibromyalgia
    Antonio Marchesoni
    UOC Day Hospital of Rheumatology and Division of Rheumatology, G Pini Orthopedic Institute, Milan, Italy
    J Rheumatol Suppl 89:29-31. 2012
    ..To compare the power Doppler ultrasonography (PDUS) pictures of peripheral entheses in patients with psoriatic arthritis (PsA) and fibromyalgia (FM)...
  4. doi request reprint Classification and clinical assessment
    A Marchesoni
    UO Day Hospital di Reumatologia, Istituto Ortopedico G Pini, Milano
    Reumatismo 64:79-87. 2012
    ..Finally, composite indices that capture several clinical manifestations of PsA have been proposed and a new instrument, the Psoriatic ARthritis Disease Activity Score (PASDAS), is currently being developed...
  5. doi request reprint Identification of the clinical features distinguishing psoriatic arthritis and fibromyalgia
    Antonio Marchesoni
    UOC Day Hospital of Rheumatology, Istituto Ortopedico Gaetano Pini, Piazza A Ferrari 1, 20122 Milan, Italy
    J Rheumatol 39:849-55. 2012
    ..To identify the clinical features that can help to distinguish between psoriatic arthritis (PsA) and fibromyalgia (FM)...
  6. doi request reprint Multidisciplinary focus on methotrexate in psoriatic disesase
    Antonio Marchesoni
    U O C Day Hospital of Rheumatology, G Pini Orthopaedic Institute, 20122 Milan, Italy
    J Rheumatol Suppl 83:56-8. 2009
    ....
  7. ncbi request reprint The Italian registry of aggressive rheumatoid arthritis -- the GIARA project
    Antonio Marchesoni
    UOC Rheumatology Day Hospital, G Pini Orthopaedic Institute, University of Milan, Milan, Italy
    J Rheumatol 34:2374-81. 2007
    ..In 1999, the Italian Society of Rheumatology started a project to determine the prevalence and clinical characteristics of aggressive rheumatoid arthritis (ARA)...
  8. doi request reprint TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice
    Antonio Marchesoni
    Day Hospital of Rheumatology, G Pini Orthopaedic Institute, Milan, Italy
    Ann N Y Acad Sci 1173:837-46. 2009
    ..Comorbidities, increasing DAS28 values and co-therapy with methotrexate were associated with a lower risk of discontinuation...
  9. doi request reprint An Italian shared dermatological and rheumatological proposal for the use of biological agents in psoriatic disease
    A Marchesoni
    UOC DH of Rheumatology, G Pini Orthopaedic Institute, Milan, Italy
    J Eur Acad Dermatol Venereol 24:578-86. 2010
    ..As psoriatic disease (PD) is a condition characterized by the combination of inflammatory skin (psoriasis) and osteo-articular manifestations (psoriatic arthritis), its treatment should cover both its clinical components...
  10. ncbi request reprint Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone
    A Marchesoni
    Rheumatology Department, University of Milan, Italy
    Rheumatology (Oxford) 42:1545-9. 2003
    ..To determine whether patients with early rheumatoid arthritis (RA) treated with cyclosporin A (CsA) and methotrexate (MTX) in combination for 12 months show a lower rate of radiographic deterioration than those treated with MTX alone...
  11. doi request reprint Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients
    Ennio Giulio Favalli
    UOC Day Hospital of Rheumatology, G Pini Orthopedic Institute, University of Milan, Milan, Italy
    Autoimmun Rev 8:266-73. 2009
    ..014), and the concomitant use of corticosteroids (p=0.029) as significant predictors of infections. There was no statistically significant difference in risk between the anti-TNFalpha agents...
  12. doi request reprint Predicting response to anti-TNF treatment in rheumatoid arthritis patients
    Fabiola Atzeni
    Rheumatology Unit, L Sacco University Hospital, Milan, Italy
    Autoimmun Rev 8:431-7. 2009
    ..To identify the clinical factors predicting failure or a good clinical response in the cohort of RA patients entered in the Lombardy Rheumatology Network (LORHEN) registry after 3 years of treatment with anti-TNF agents...
  13. ncbi request reprint The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept
    Ennio Lubrano
    Department of Health Sciences, School of Medicine, University of Molise, Campobasso, Italy
    Clin Exp Rheumatol 29:80-4. 2011
    ..To investigate the effectiveness of etanercept on axial manifestations of a group of patients with established psoriatic arthritis (PsA)...
  14. doi request reprint Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry
    Francesca Bobbio Pallavicini
    Rheumatology Department, IRCCS Policlinico S Matteo, University of Pavia, Pavia, Italy
    Autoimmun Rev 9:175-80. 2010
    ..The objective was to compare cancer risk in a RA cohort population treated with TNF antagonists, and identify the characteristics of the patients at higher risk...
  15. doi request reprint Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal
    Roberto Caporali
    Rheumatology Unit, University of Pavia, IRCCS Policlinico S Matteo Foundation, 27100 Pavia, Italy
    Autoimmun Rev 8:274-80. 2009
    ..As the first published registry of anti-TNFalpha-treated patients in Italy, Lombardy Rheumatology Network (LORHEN) is already making its contribution in this direction...
  16. doi request reprint The radiological assessment of axial involvement in psoriatic arthritis
    Ennio Lubrano
    Rheumatology Unit, Department of Health Sciences, University of Molise, Campobasso, Italy
    J Rheumatol Suppl 89:54-6. 2012
    ..Recently, a study assessed the sensitivity to change of BASRI, m-SASSS, and PASRI, and showed that these 3 instruments provided a moderate sensitivity to change but high specificity to detect the true changes...
  17. doi request reprint Is the Nail Psoriasis Severity Index reliable in the assessment of nail psoriasis by rheumatologists?
    Ennio Lubrano
    University of Molise, Campobasso, Italy
    Arthritis Care Res (Hoboken) 64:455-8. 2012
    ....
  18. doi request reprint Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry
    Fabiola Atzeni
    Rheumatology Unit, L Sacco University Hospital, Milan, Italy
    Autoimmun Rev 12:225-9. 2012
    ..To evaluate the risk of serious infections (SIs) in RA patients receiving anti-TNF therapy on the basis of the data included in the GISEA register...
  19. ncbi request reprint Five-year survival on infliximab in rheumatoid arthritis patients: analysis from an Italian registry (GISEA) by different calendar years
    Florenzo Iannone
    Rheumatology Unit, University of Bari, Italy
    Clin Exp Rheumatol 33:524-30. 2015
    ..To assess long-term drug survival and effectiveness in biological drug-naïve patients with rheumatoid arthritis (RA), starting infliximab as first treatment, in the period 2000-2009, comparing different calendar years...
  20. doi request reprint The Definition and Measurement of Axial Psoriatic Arthritis
    Ennio Lubrano
    From the Academic Rheumatology Unit, Department of Medicine and Health Sciences, University of Molise, Campobasso Rheumatology Department, Istituto Ortopedico G Pini, Milan Rheumatology Department of Lucania, S Carlo Hospital, Potenza and Madonna Delle Grazie Matera, Potenza and Matera Rheumatology Unit, Department of Medical Sciences, University of Cagliari, Cagliari Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padua and Rheumatology Unit, Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy E Lubrano, MD, PhD, Aggregate Professor of Rheumatology, Academic Rheumatology Unit, Department of Medicine and Health Sciences, University of Molise W J Parsons, Bsc, MPH, Medical Statistician, Academic Rheumatology Unit, Department of Medicine and Health Sciences, University of Molise A Marchesoni, MD, Consultant Rheumatologist, Rheumatology Department, Istituto Ortopedico G Pini I Olivieri, MD, Consultant Rheumatologist and Head of Rheumatology Department, Department of Surgery
    J Rheumatol Suppl 93:40-2. 2015
    ..Finally, there is no evidence to support treatment of axPsA with traditional disease-modifying antirheumatic drugs, while a "leap" to biologic agents is the only treatment after failure with nonsteroidal antiinflammatory drugs. ..
  21. ncbi request reprint Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology
    Carlo Salvarani
    Rheumatology Unit, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy
    Clin Exp Rheumatol 29:S28-41. 2011
    ..To update the 2006 Italian Society for Rheumatology recommendations for the use of biologic (TNF-α blocking) agents in the treatment of psoriatic arthritis (PsA)...
  22. doi request reprint Predictors of response to anti-TNF therapy in RA patients with moderate or high DAS28 scores
    Fabiola Atzeni
    Rheumatology Unit, L Sacco University Hospital of Milan, Milan, Italy Electronic address
    Joint Bone Spine 81:37-40. 2014
    ..2-5.1 [MDA] and high>5.1 [HDA])...
  23. doi request reprint Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-α drugs: an Italian multicenter study
    Ennio Lubrano
    Academic Rheumatology Unit, Department of Medicine and Health Science, University of Molise, Campobasso Dipartimento di Medicina Interna e Specialità Mediche, L Unità Operativa Complessa UOC di Reumatologia Sapienza Università di Roma, Rome Rheumatology Unit, Orthopedic Institute G Pini, Milan Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza Rheumatology Unit, Department of Medicine, Dipartimento di Medicina DIMED, University of Padua, Padua S C Reumatologia, Dipartimento Medicina Interna e Specialità Mediche Arcispedale Santa Maria Nuova, Azienda Ospedaliera IRCCS di Reggio Emilia, Reggio Emilia, Italy E Lubrano, MD, PhD, Academic Rheumatology Unit, Department of Medicine and Health Science, University of Molise F M Perrotta, MD, Dipartimento di Medicina Interna e Specialita Mediche, UOC di Reumatologia Sapienza Università di Roma A Marchesoni, MD, Rheumatology Unit, Orthopedic Institute G Pini S D Angelo, MD I Olivieri, MD, Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera R Ramonda, MD L Punzi, MD, Rheumatology Unit, DIMED, Georgia
    J Rheumatol 42:258-63. 2015
    ..The Assessment of SpondyloArthritis international Society (ASAS) 20, ASAS40, and Ankylosing Spondylitis Disease Activity Score were also calculated...
  24. doi request reprint Switching rheumatoid arthritis treatments: an update
    Fabiola Atzeni
    Rheumatology Unit, L Sacco University Hospital, Milan, Italy
    Autoimmun Rev 10:397-403. 2011
    ..However, many RA patients can be successfully treated with a second TNF antagonist, especially those discontinuing the first because of secondary failure or adverse events...
  25. doi request reprint New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol
    Alberto Cauli
    From the Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Monserrato Rheumatology Unit, Department of Medicine and Health Sciences, University of Molise, Campobasso and Azienda Ospedaliero Universitaria, Day Hospital di Reumatologia, Istituto Ortopedico G Pini, Milan, Italy A Cauli, MD, PhD M Piga, MD, Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari E Lubrano, MD, PhD, Rheumatology Unit, Department of Medicine and Health Sciences, University of Molise A Marchesoni, MD, Azienda Ospedaliero Universitaria, Day Hospital di Reumatologia, Istituto Ortopedico G Pini A Floris, MD A Mathieu, MD, Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari
    J Rheumatol Suppl 93:70-2. 2015
    ..This article summarizes available data on its clinical efficacy and safety profile in the treatment of patients with PsA. ..
  26. doi request reprint Patient's Global Assessment as an Outcome Measure for Psoriatic Arthritis in Clinical Practice: A Surrogate for Measuring Low Disease Activity?
    Ennio Lubrano
    From the Academic Rheumatology Unit, Department of Medicine and Health Sciences, University of Molise, Campobasso Department of Clinical and Medical Therapy, Sapienza University, Rome Rheumatology Unit, Orthopedic Institute G Pini, Milan, Italy E Lubrano, MD, PhD, Aggregate Professor of Rheumatology, Academic Rheumatology Unit, Department of Medicine and Health Sciences, University of Molise F M Perrotta, MD, Specialist Registrar, Department of Clinical and Medical Therapy, Sapienza University W J Parsons, MSc, MPH, Medical Statistician, Academic Rheumatology Unit, Department of Medicine and Health Sciences, University of Molise A Marchesoni, MD, Consultant Rheumatologist, Rheumatology Unit, Orthopedic Institute G Pini
    J Rheumatol 42:2332-8. 2015
    ....
  27. doi request reprint Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs
    Fabio Massimo Perrotta
    From the Academic Rheumatology Unit, Department of Medicine and Health Science Vincenzo Tiberio, University of Molise, Campobasso Rheumatology Unit, Orthopedic Institute G Pini, Milan, Italy F M Perrotta, MD, PhD, fellow in Translational and Clinical Medicine, Academic Rheumatology Unit, Department of Medicine and Health Science Vincenzo Tiberio, University of Molise A Marchesoni, MD, Consultant Rheumatologist, Rheumatology Unit, Orthopedic Institute G Pini E Lubrano, MD, PhD, Aggregate Professor of Rheumatology and Consultant Rheumatologist, Academic Rheumatology Unit, Department of Medicine and Health Science Vincenzo Tiberio, University of Molise
    J Rheumatol 43:350-5. 2016
    ..Disease characteristics and predictors of MDA were also evaluated...
  28. doi request reprint High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register
    Florenzo Iannone
    Interdisciplinary Department of Medicine, Rheumatology Unit, Policlinico, Piazza G Cesare 11, 70124, Bari, Italy
    Clin Rheumatol 33:31-7. 2014
    ..These findings may aid clinicians to choose the best strategy to treat RA. ..
  29. doi request reprint Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies
    Ennio Giulio Favalli
    Department of Rheumatology, Gaetano Pini Institute and Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy
    Rheumatology (Oxford) 53:1664-8. 2014
    ....
  30. ncbi request reprint Polymorphism in the matrix metalloproteinase-1 promoter gene and severity of rheumatoid arthritis
    Marco Massarotti
    J Rheumatol 29:2241; author reply 2242. 2002
  31. ncbi request reprint Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs -- comparison of drugs and adverse reactions
    Philip S Helliwell
    Academic Unit of Musculoskeletal and Rehabilitation Medicine, University of Leeds, Leeds, UK
    J Rheumatol 35:472-6. 2008
    ..Although it seems likely that these conditions have a different pathogenesis, the drugs used to treat them are the same. Our study used a cross-sectional clinical database to compare drug use and side-effect profile in these 2 diseases...
  32. ncbi request reprint Polymorphism in the stromelysin 1 (matrix metalloproteinase 3) promoter gene and severity of rheumatoid arthritis: comment on the article by Constantin et al
    Marco Massarotti
    Arthritis Rheum 48:2695-6. 2003
  33. ncbi request reprint A comparison of the performance characteristics of classification criteria for the diagnosis of psoriatic arthritis
    William J Taylor
    Rheumatology and Rehabilitation Research Unit, University of Leeds, UK
    Semin Arthritis Rheum 34:575-84. 2004
    ..To compare the accuracy of published classification criteria for the diagnosis of psoriatic arthritis (PsA) and to see whether data-derived classification criteria would be more accurate...
  34. ncbi request reprint Antibodies to cyclic citrullinated peptides in psoriatic arthritis: do classification criteria affect study results?
    Antonio Marchesoni
    J Rheumatol 33:435; author reply 436-7. 2006
  35. ncbi request reprint Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis
    Ennio Giulio Favalli
    Arthritis Rheum 51:301-2. 2004